EDAP TMS S.A. to Participate in International Urology Conferences LYON, France -- EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, today announces it is actively participating in the Societe Internationale d'Urologie (SIU)
EDAP and HealthTronics in Discussions Realigning US Market Entry;
Ablatherm RPP Success Growing Europe;
Lithotripsy Returns to Profitability - Solid Cash Position for Continued Growth
Ablatherm-HIFU featured in UroToday.com Electronic Newsletter EDAP and Ablatherm-HIFU were recently featured in an email distributed by UroToday.com to more than 10,000 urologists advising them of the site's HIFU Resource Center. Urotoday.com, located at http://www.urotoday.com , is one of the top
The following article appeared September 27, 2006 in WRAL.com serving the Raleigh-Durham & Fayetteville, North Carolina areas. The story can be viewed at http://www.wral.com/health/9947426/detail.html.
Ultrasound Waves Being Used To Treat Prostate Cancer
Webcast: EDAP Presentation at Roth Capital Conference EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, presented at the Roth Capital Partners New York Conference on September 6, 2006 at the Westin Time Square Hotel in New
EDAP TMS S.A. to Present at Roth Capital Conference in New York Lyon, France, August 24, 2006 - EDAP TMS S.A. (Nasdaq: EDAP) , the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, announced management will present at the Roth Capital Partners New York
EDAP TMS S.A. to Release 2006 Second Quarter Financial Results August 8, 2006 Lyon, France, August 3, 2006 - EDAP TMS S.A. (Nasdaq: EDAP) , will release its second quarter financial results for the period ending June 30, 2006 on Tuesday, August 8, 2006 after the market close.